top of page

Longboard Pharma's CEO describes today's open label extension data for bexicaserin in Developmental and Epileptic Encephalopathies

Kevin Lind explains how patients randomized to therapy and placebo crossover patients are seeing comparable reductions in seizure levels. He also discusses the regulatory path ahead as this programs looks to enter pivotal study(ies).


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight


Breakthrough Properties is a life science real estate company that is exclusively focused on delivering cutting-edge environments for the life science industry. With a portfolio of roughly 5 million square feet across the US, UK and continental Europe, Breakthrough has emerged as a leading partner for high-growth biotechs and pharmas around the world. 

bottom of page